Fixed-Dose Trial in Early Parkinson's Disease (PD)
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics
(PK) of 2 fixed doses of tavapadon and placebo in participants with early PD.